Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Up 575.0% in June

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totaling 22,107 shares, an increase of 575.0% from the May 31st total of 3,275 shares. Based on an average daily volume of 263,781 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company’s stock are short sold.

Barinthus Biotherapeutics Stock Down 1.7%

Shares of BRNS traded down $0.01 during midday trading on Friday, hitting $0.71. The company had a trading volume of 703 shares, compared to its average volume of 57,080. The stock has a market cap of $28.88 million, a price-to-earnings ratio of -0.55 and a beta of -0.40. The company’s 50 day moving average price is $0.67 and its 200 day moving average price is $0.66. Barinthus Biotherapeutics has a 52 week low of $0.51 and a 52 week high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.14.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the business. Rangeley Capital LLC lifted its position in shares of Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after buying an additional 75,024 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Barinthus Biotherapeutics by 115.8% in the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after purchasing an additional 76,800 shares during the last quarter. Finally, Baird Financial Group Inc. grew its stake in Barinthus Biotherapeutics by 108.2% during the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after buying an additional 100,000 shares during the last quarter. Institutional investors and hedge funds own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.